

# Rana Ahmed Youness

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/607163/publications.pdf>

Version: 2024-02-01

38  
papers

866  
citations

430874

18  
h-index

477307

29  
g-index

39  
all docs

39  
docs citations

39  
times ranked

647  
citing authors

#	ARTICLE	IF	CITATIONS
1	PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 483-489.	2.1	12
2	Hindering the Synchronization Between miR-486-5p and H19 lncRNA by Hesperetin Halts Breast Cancer Aggressiveness Through Tuning ICAM-1. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 586-595.	1.7	20
3	Uncoupling tumor necrosis factor- $\alpha$ and interleukin-10 at tumor immune microenvironment of breast cancer through miR-17-5p/MALAT-1/H19 circuit. <i>Biocell</i> , 2022, 46, 769-783.	0.7	10
4	Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2022, 27, 79-99.	2.7	13
5	MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated quercetin glycoside alters immunogenic and oncogenic profiles of breast cancer. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1281-1293.	3.1	27
6	An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR-20a-MICA/B axis. <i>Natural Product Research</i> , 2021, 35, 3126-3130.	1.8	28
7	Targeting hydrogen sulphide signaling in breast cancer. <i>Journal of Advanced Research</i> , 2021, 27, 177-190.	9.5	46
8	miRNA-506-3p Directly Regulates rs10754339 (A/G) in the Immune Checkpoint Protein B7-H4 in Breast Cancer. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2021, 9, 346-353.	1.2	12
9	Recent Advances in Tannic Acid (Gallotannin) Anticancer Activities and Drug Delivery Systems for Efficacy Improvement; A Comprehensive Review. <i>Molecules</i> , 2021, 26, 1486.	3.8	55
10	25P Promising immuno-oncological role of rosemary against breast cancer through altering miR-17-5p, MALAT-1, H19 and tumour microenvironment. <i>Annals of Oncology</i> , 2021, 32, S11.	1.2	2
11	14P MALAT-1: A novel lncRNA modulating STAT-3 regulated cystathionine- $\beta$ -lyase (CSE) in breast cancer. <i>Annals of Oncology</i> , 2021, 32, S7.	1.2	2
12	30P Expression signature of Let-7a, miR-34a and miR-486-5p in young triple-negative breast cancer patients overexpressing PDL1: A step towards precision immuno-oncology. <i>Annals of Oncology</i> , 2021, 32, S33.	1.2	1
13	lncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2 $\alpha$ -induced nitric oxide production. <i>Journal of Cellular Physiology</i> , 2021, 236, 5362-5372.	4.1	35
14	What is beyond lncRNAs in breast cancer: A special focus on colon cancer-associated Transcript-1 (CCAT-1). <i>Non-coding RNA Research</i> , 2021, 6, 174-186.	4.6	14
15	30P Differential expression of miR-873, miR-181a and miR-17-5p and their correlation with immune checkpoints PD-L1 and CD155 among hepatocellular carcinoma patients. <i>Annals of Oncology</i> , 2021, 32, S1385-S1386.	1.2	1
16	134P Drugless nanoparticles tune-up immune components at triple negative breast cancer tumor microenvironment milieu. <i>Annals of Oncology</i> , 2021, 32, S1435.	1.2	1
17	A methoxylated quercetin glycoside harnesses HCC tumor progression in a TP53/miR-15/miR-16 dependent manner. <i>Natural Product Research</i> , 2020, 34, 1475-1480.	1.8	40
18	lncRNA H19/miR-486-5p/miR-17-5p: A novel immunoregulatory loop regulating TNBC cellular recognition by cytotoxic T lymphocytes and natural killer cells. <i>European Journal of Cancer</i> , 2020, 138, S56-S57.	2.8	1

#	ARTICLE	IF	CITATIONS
19	Interplay between the Pan-Tumor Suppressor miR-939-5p and the oncogenic lncRNA-HEIH dually curbs Hydrogen Sulphide and Nitric Oxide production in breast cancer cells. <i>European Journal of Cancer</i> , 2020, 138, S70.	2.8	1
20	6OP Curbing the interplay between miR-939-5p and HEIH lncRNA by EGCG represses hydrogen sulphide machinery and hinders breast cancer progression. <i>Annals of Oncology</i> , 2020, 31, S1235.	1.2	2
21	MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions. <i>Non-coding RNA Research</i> , 2020, 5, 11-21.	4.6	58
22	miR-486-5p and miR-17-5p: Novel Immunomodulatory Non-coding RNAs Drawn Downstream 3â€²-O-Acetylvitexin in Triple Negative Breast Cancer. <i>European Journal of Cancer</i> , 2020, 138, S70.	2.8	2
23	Why natural killer cells in triple negative breast cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 464-476.	2.3	33
24	The long noncoding RNA sONE represses tripleâ€negative breast cancer aggressiveness through inducing the expression of miRâ€34a, miRâ€15a, miRâ€16, and letâ€7a. <i>Journal of Cellular Physiology</i> , 2019, 234, 4.1 20286-20297.	4.1	49
25	Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. <i>Archives of Virology</i> , 2019, 164, 1587-1595.	2.1	27
26	Long non-coding RNAs: Functional regulatory players in breast cancer. <i>Non-coding RNA Research</i> , 2019, 4, 36-44.	4.6	82
27	A Novel Immunological Role of Hydrogen Sulphide in Shaping Natural Killer Cells Cytotoxicity in Breast Cancer Patients. <i>Annals of Oncology</i> , 2019, 30, xi39.	1.2	0
28	Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC. <i>Annals of Oncology</i> , 2019, 30, xi57.	1.2	3
29	miR-486-5p Counteracts the Shedding of MICA/B and CD155 Immune-Ligands in TNBC Patients. <i>Annals of Oncology</i> , 2019, 30, xi60-xi61.	1.2	2
30	Destabilizing the interplay between miR-1275 and IGF2BPs by <i>Tamarix articulata</i> and quercetin in hepatocellular carcinoma. <i>Natural Product Research</i> , 2018, 32, 2217-2220.	1.8	57
31	PO-347 sONE, a novel tumour suppressor lncRNA, with diminished expression level in young triple negative breast cancer (TNBC) patients with lymphnode metastasis and large tumour size. <i>ESMO Open</i> , 2018, 3, A364-A365.	4.5	2
32	Crosstalk between hesperetin and miR-486-5p in triple-negative breast cancer (TNBC): An approach towards precision medicine. <i>Annals of Oncology</i> , 2018, 29, vi28-vi29.	1.2	5
33	miR-4317, a promising player tuning the anti-tumor armamentarium against breast cancer. <i>Annals of Oncology</i> , 2018, 29, vi18-vi19.	1.2	1
34	A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 80, 12-23.	2.7	43
35	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. <i>Growth Factors</i> , 2017, 35, 76-87.	1.7	40
36	Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-â€/BAFF axis pathway by miR-155. <i>Growth Factors</i> , 2017, 35, 49-60.	1.7	23

#	ARTICLE	IF	CITATIONS
37	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. Growth Factors, 2016, 34, 128-140.	1.7	49
38	MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. Oncology Letters, 2016, 12, 2567-2573.	1.8	66